Clinical utilization of airway inflammatory biomarkers in the prediction and monitoring of clinical outcomes in patients with chronic obstructive pulmonary disease

References

• Singh D, Agusti A, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019 May;53(5):1900164.
   PubMed Web of Science ®Google Scholar
• Stockley RA, Halpin DMG, Celli BR, et al. Chronic obstructive pulmonary disease biomarkers and their interpretation. Am J Respir Crit Care Med. 2019 May;199(10):1195–1204. doi: 10.1164/RCCM.201810-1860SO
   PubMed Web of Science ®Google Scholar
• Agustí A, Celli BR, Criner GJ, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Eur Respir J. 2023 Apr;61(4):2300239.
   PubMed Web of Science ®Google Scholar
• Varmaghani M, Dehghani M, Heidari E, et al. Global prevalence of chronic obstructive pulmonary disease: systematic review and meta-analysis. East Mediterr Health J. 2019;25(1):47–57. doi:10.26719/EMHJ.18.014
   PubMed Web of Science ®Google Scholar
• Viegi G, Maio S, Fasola S, et al. Global burden of chronic respiratory diseases. J Aerosol Med Pulmonary Drug Delivery. 2020 Jul;33(4):171–177. doi: 10.1089/JAMP.2019.1576
   PubMed Web of Science ®Google Scholar
• Jones TPW, Brown J, Hurst JR, et al. COPD exacerbation phenotypes in a real-world five year hospitalisation cohort. Respir med. 2020 Jun;167:105979. doi: 10.1016/J.RMED.2020.105979
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002 Oct;57(10):847–852. doi: 10.1136/THORAX.57.10.847
   PubMed Web of Science ®Google Scholar
• Spencer S, Calverley PMA, Burge PS, et al. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004 May;23(5):698–702. doi: 10.1183/09031936.04.00121404
   PubMed Web of Science ®Google Scholar
• Lapperre T, Bodtger, U, Klein, DK et al. Dysfunctional breathing impacts symptom burden in Chronic Obstructive Pulmonary Disease (COPD). Eur Respir J. 2020 Sep;56(suppl 64):124. doi: 10.1183/13993003.CONGRESS-2020.124
   Google Scholar
• Lewthwaite H, Jensen D, Ekström M. How to assess breathlessness in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2021;16:1581–1598. doi: 10.2147/COPD.S277523
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Milne KM, James MD, et al. Dyspnea in COPD: new mechanistic insights and management implications. Adv Ther. 2020 Jan;37(1):41–60. doi: 10.1007/S12325-019-01128-9
   PubMed Web of Science ®Google Scholar
• Carter JA, Burke HB. CRP-Guided antibiotic therapy for acute COPD exacerbation: a randomized control trial. J Gen Intern Med. 2021 Jul;36(7):2194–2196. doi: 10.1007/S11606-020-06053-0
   PubMed Web of Science ®Google Scholar
• Celli BR, Locantore, N, Yates J. et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012 May;185(10):1065–1072. doi: 10.1164/RCCM.201110-1792OC
   PubMed Web of Science ®Google Scholar
• Mirza S, Benzo R. Chronic obstructive pulmonary disease phenotypes: implications for care. Mayo Clin Proc. 2017 Jul;92(7):1104–1112. doi: 10.1016/J.MAYOCP.2017.03.020
   PubMed Web of Science ®Google Scholar
• Szalontai K, Gémes N, Furák J, et al. Chronic obstructive pulmonary disease: epidemiology, biomarkers, and paving the way to lung cancer. J Clin Med. 2021 Jul;10(13):2889.
   PubMed Web of Science ®Google Scholar
• Saetta M, Di stefano A, TURATO G, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(3):822–826. doi: 10.1164/AJRCCM.157.3.9709027
   PubMed Web of Science ®Google Scholar
• Di Stefano A, Capelli A, Lusuardi M, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med. 1998;158(4):1277–1285. doi: 10.1164/AJRCCM.158.4.9802078
   PubMed Web of Science ®Google Scholar
• George L, Brightling CE. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis. 2016;7(1):34–51. doi: 10.1177/2040622315609251
   PubMed Web of Science ®Google Scholar
• Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. Eur Respir. Aug 2019;54(2). doi: 10.1183/13993003.00651-2019
   Web of Science ®Google Scholar
• Tilley AE, Walters MS, Shaykhiev R, et al. Cilia dysfunction in lung disease. Annu Rev Physiol. 2015 Feb;77:379–406. doi: 10.1146/ANNUREV-PHYSIOL-021014-071931
   PubMed Web of Science ®Google Scholar
• Bosken CH, Wiggs BR, Pare PD, et al. Small airway dimensions in smokers with obstruction to airflow. Am Rev Respir Dis. 1990;142(3):563–570. doi: 10.1164/AJRCCM/142.3.563
   PubMedGoogle Scholar
• Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004 Jun;350(26):2645–2653.
   PubMed Web of Science ®Google Scholar
• Paplińska-Goryca M, Nejman-Gryz P, Górska K, et al. Expression of Inflammatory Mediators in Induced Sputum: Comparative Study in Asthma and COPD. Adv Exp Med Biol. 2018;1040:101–112. doi: 10.1007/5584_2016_165
   PubMed Web of Science ®Google Scholar
• Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007 May;29(5):906–913.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xu J, Meng Y, et al. Role of inflammatory cells in airway remodeling in COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:3341–3348. doi: 10.2147/COPD.S176122
   PubMed Web of Science ®Google Scholar
• Proboszcz M, Mycroft K, Paplinska-Goryca M, et al. Relationship between blood and induced sputum eosinophils, bronchial hyperresponsiveness and reversibility of airway obstruction in mild-to-moderate chronic obstructive pulmonary disease. COPD: J Chronic Obstructive Pulmonary Dis. 2019 Nov;16(5–6):354–361.
   PubMed Web of Science ®Google Scholar
• Brightling CE. Chronic obstructive pulmonary disease phenotypes, biomarkers, and prognostic indicators. Allergy asthma proc. 2016 Nov;37(6):432–438. doi: 10.2500/AAP.2016.37.3996
   PubMed Web of Science ®Google Scholar
• Scambler T, Holbrook J, Savic S, et al. Autoinflammatory disease in the lung. Immunology. 2018 Aug;154(4):563–573. doi: 10.1111/IMM.12937
   PubMed Web of Science ®Google Scholar
• Alobaidi N, Stockley J, Stockley R, et al. An overview of exacerbations of chronic obstructive pulmonary disease: can tests of small airways’ function guide diagnosis and management?. Ann Thorac Med. 2020 Apr;15(2):54. doi: 10.4103/ATM.ATM_323_19
   PubMed Web of Science ®Google Scholar
• P. Jones P Jones W, and Forde Y, ST george’s respiratory questionnaire for copd patients (SGRQ-C) Manual. 2023 [cited 2024 Jan 11]. Available from: http://chestjournal.chestpubs.org/content/132/2/456.full.html
   Google Scholar
• Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009 Sep;34(3):648–654. doi: 10.1183/09031936.00102509
   PubMed Web of Science ®Google Scholar
• Jones PW, Shahrour N, Nejjari C, et al. Psychometric evaluation of the COPD assessment test: data from the BREATHE study in the Middle East and North Africa region. Respir med. 2012 Dec;106(SUPPL. 2):S86–S99.
   PubMedGoogle Scholar
• Jones PW, Brusselle G, Dal Negro RW, et al. Properties of the COPD assessment test in a cross-sectional European study. Eur Respir J. 2011 Jul;38(1):29–35.
   PubMed Web of Science ®Google Scholar
• Il Gil H, Zo S, Jones PW, et al. Clinical characteristics of COPD patients according to COPD assessment test (CAT) score level: cross-sectional study. Int J Chron Obstruct Pulmon Dis. 2021;16:1509–1517. doi: 10.2147/COPD.S297089
   PubMed Web of Science ®Google Scholar
• Kelly JL, Bamsey O, Smith C, et al. Health status assessment in routine clinical practice: the chronic obstructive pulmonary disease assessment test score in outpatients. Respiration. 2012 Aug;84(3):193–199.
   PubMed Web of Science ®Google Scholar
• Pothirat C, Chaiwong W, Deesomchok A, et al. Detection of acute deterioration in health status visit among COPD patients by monitoring COPD assessment test score. Int J Chron Obstruct Pulmon Dis. 2015 Feb;10:277–282. doi: 10.2147/COPD.S76128
   PubMed Web of Science ®Google Scholar
• Corlateanu A, Plahotniuc A, Corlateanu O, et al. Multidimensional indices in the assessment of chronic obstructive pulmonary disease. Respir med. 2021 Aug;185:106519. doi: 10.1016/J.RMED.2021.106519
   PubMed Web of Science ®Google Scholar
• Celli B, Tetzlaff K, Criner G, et al. The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease Stratification Tool. Insights from the COPD Biomarker Qualification Consortium. Am J Respir Crit Care Med. 2016 Dec;194(12):1483–1493.
   PubMed Web of Science ®Google Scholar
• Pinto-Plata VM, Cote C, Cabral H, et al. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J. 2004 Jan;23(1):28–33. doi: 10.1183/09031936.03.00034603
   PubMed Web of Science ®Google Scholar
• Casanova C, Cote C, Marin JM, et al. Distance and oxygen desaturation during the 6-min walk test as predictors of long-term mortality in patients with COPD. Chest. 2008;134(4):746–752. doi: 10.1378/CHEST.08-0520
   PubMed Web of Science ®Google Scholar
• McDonald VM, Gibson PG. Treatable Traits in Asthma and COPD. Arch Bronconeumol. 2022 Aug;58(8):583–585. doi: 10.1016/J.ARBRES.2021.07.003
   PubMed Web of Science ®Google Scholar
• Papi A, ROMAGNOLI M, BARALDO S, et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162(5):1773–1777. doi: 10.1164/AJRCCM.162.5.9910112
   PubMed Web of Science ®Google Scholar
• Caramori G, Casolari P, Barczyk A, et al. COPD immunopathology. Semin Immunopathol. 2016 Jul;38(4):497–515. doi: 10.1007/S00281-016-0561-5
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016 Jul;138(1):16–27. doi: 10.1016/J.JACI.2016.05.011
   PubMed Web of Science ®Google Scholar
• Antus B, Paska C, Barta I. Predictive Value of Exhaled Nitric Oxide and Blood Eosinophil Count in the Assessment of Airway Eosinophilia in COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:2025–2035. doi:10.2147/COPD.S257965
   PubMed Web of Science ®Google Scholar
• Eickmeier O, Huebner M, Herrmann E, et al. Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function. Cytokine. 2010 May;50(2):152–157.
   PubMed Web of Science ®Google Scholar
• Esther CR, O’Neal WK, Anderson WH, et al. Identification of sputum biomarkers predictive of pulmonary exacerbations in COPD. Chest. 2022 May;161(5):1239–1249.
   PubMed Web of Science ®Google Scholar
• Blood and sputum biomarkers in COPD and asthma: a review - PubMed. [cited 2024 Jan 11]. Available from: https://pubmed.ncbi.nlm.nih.gov/26957273/
   Google Scholar
• Simpson JL, Scott R, Boyle MJ, et al. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006 Jan;11(1):54–61. doi: 10.1111/J.1440-1843.2006.00784.X
   PubMed Web of Science ®Google Scholar
• Brightling CE, Bleecker ER, Panettieri RA, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. The Lancet Respiratory Medicine. 2014;2(11):891–901. doi: 10.1016/S2213-2600(14)70187-0
   PubMed Web of Science ®Google Scholar
• Eltboli O, Bafadhel M, Hollins F, et al. COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils. BMC Pulm Med. 2014 Jul;14(1). doi: 10.1186/1471-2466-14-112
   PubMedGoogle Scholar
• Chen M, Xu K, He Y, et al. CC16 as an inflammatory biomarker in induced sputum reflects chronic obstructive pulmonary disease (COPD) severity. Int J Chron Obstruct Pulmon Dis. 2023;18:705–717. doi: 10.2147/COPD.S400999
   PubMed Web of Science ®Google Scholar
• Ghebre MA, Bafadhel M, Desai D, et al. Biological clustering supports both “Dutch” and “British” hypotheses of asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2015 Jan;135(1):63–72.e10.
   PubMed Web of Science ®Google Scholar
• Kim YW, Kwon BS, Lim SY, et al. Diagnostic value of bronchoalveolar lavage and bronchial washing in sputum-scarce or smear-negative cases with suspected pulmonary tuberculosis: a randomized study. Clin Microbiol Infect. 2020 Jul;26(7):911–916.
   PubMed Web of Science ®Google Scholar
• Patel PH, Antoine MH, Ullah S, Bronchoalveolar Lavage StatPearls. 2022 Aug [cited 2024 Jan 11]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430762/
   Google Scholar
• Rutgers SR, Timens W, Kaufmann HF, et al. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J. 2000 Jan;15(1):109–115. doi: 10.1183/09031936.00.15110900
   PubMed Web of Science ®Google Scholar
• Yang H, Wen X, Wu F, et al. Inter-relationships among neutrophilic inflammation, air trapping and future exacerbation in COPD: an analysis of ECOPD study. BMJ Open Respir Res. 2023 Apr;10(1):e001597.
   PubMed Web of Science ®Google Scholar
• Sharma K, Neutrophil-Lymphocyte Ratio as a Section Predictor of COPD Exacerbations: A Cross-sectional Study. [cited 2024 Jan 11]. Available from: https://jcdr.net/articles/PDF/17337/59293_CE(AD)_F(IS)_PF1(SC_KM)_PFA(SC_KM)_PN(KM).pdf
   Google Scholar
• Ryu MH, Yun JH, Morrow JD, et al. Blood gene expression and immune cell subtypes associated with chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2023 Aug;208(3):247–255.
   PubMed Web of Science ®Google Scholar
• Singh R, Belchamber KBR, Fenwick PS, et al. Defective monocyte-derived macrophage phagocytosis is associated with exacerbation frequency in COPD. Respir Res. 2021 Dec;22(1):1–11.
   PubMed Web of Science ®Google Scholar
• Vlahos R, Bozinovski S. Role of alveolar macrophages in chronic obstructive pulmonary disease. Front Immunol. 2014;5(SEP). doi: 10.3389/FIMMU.2014.00435
   PubMedGoogle Scholar
• Frankenberger M, Eder C, Hofer TPJ, et al. Chemokine expression by small sputum macrophages in COPD. Mol Med. 2011 Jul;17(7–8):762–770.
   PubMed Web of Science ®Google Scholar
• Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006 May;173(10):1114–1121.
   PubMed Web of Science ®Google Scholar
• Tinè M, Neri T, Biondini D, et al. Do Circulating extracellular vesicles strictly reflect bronchoalveolar lavage extracellular vesicles in COPD? Int J Mol Sci. 2023 Feb;24(3):2966.
   PubMed Web of Science ®Google Scholar
• Tan WC, Bourbeau J, Nadeau G, et al. High eosinophil counts predict decline in FEV1: results from the CanCOLD study. Eur Respir J. 2021 May;57(5):2000838.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liang L-R, Zhang S, et al. Blood eosinophilia and Its stability in hospitalized COPD exacerbations are associated with lower risk of all-cause mortality. Int J COPD. 2020;15:1123–1134. doi: 10.2147/COPD.S245056
   Google Scholar
• Kersul AL, Iglesias A, Ríos Á, et al. Mecanismos moleculares de inflamación durante las agudizaciones de la enfermedad pulmonar obstructiva crónica. Arch Bronconeumol. 2011 Apr;47(4):176–183.
   PubMed Web of Science ®Google Scholar
• Li J, Liang L, Feng L, et al. The prognostic value of blood eosinophil level in AECOPD is influenced by corticosteroid treatment during hospitalization. J Inflamm Res. 2023;16:3233–3243. doi: 10.2147/JIR.S421605
   PubMed Web of Science ®Google Scholar
• Cui Y, Chen Y. Blood eosinophils in chronic obstructive pulmonary disease: A potential biomarker. J Transl Int Med. 2023 Sep;11(3):193–197. doi: 10.2478/JTIM-2023-0096
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011 Sep;184(6):662–671.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012 Jul;186(1):48–55.
   PubMed Web of Science ®Google Scholar
• Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014 Dec;44(6):1697–1700. doi: 10.1183/09031936.00162414
   PubMed Web of Science ®Google Scholar
• Christenson SA, Steiling K, van den Berge M, et al. Asthma–COPD Overlap. clinical relevance of genomic signatures of Type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015 Apr;191(7):758–766.
   PubMed Web of Science ®Google Scholar
• Fujimoto K, Yasuo M, Urushibata K, et al. Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. Eur Respir J. 2005 Apr;25(4):640–646. doi: 10.1183/09031936.05.00047504
   PubMed Web of Science ®Google Scholar
• Hastie AT, Martinez FJ, Curtis JL, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017 Dec;5(12):956–967.
   PubMed Web of Science ®Google Scholar
• Negewo NA, McDonald V, Baines K, et al. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. Int J Chron Obstruct Pulmon Dis. 2016 Jul;11(1):1495–1504.
   PubMedGoogle Scholar
• Ho CMG, Milne S, Li X, et al. Airway eosinophilia on bronchoalveolar lavage and the risk of exacerbations in COPD. Biomedicines. 2022 Jun;10(6):1412.
   PubMed Web of Science ®Google Scholar
• Safwat T, El-Sheikh M, El-Sayed A, et al. Peripheral blood eosinophil count as a biomarker of exacerbation in stable chronic obstructive pulmonary disease outpatients: a prospective observational study. Egypt J Chest Dis Tuberc. 2023;72(3):313. doi:10.4103/ECDT.ECDT_120_22
   Web of Science ®Google Scholar
• Zanini A, Cherubino F, Zampogna E, et al. Bronchial hyperresponsiveness, airway inflammation, and reversibility in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015 Jun;10:1155–1161. doi: 10.2147/COPD.S80992
   PubMed Web of Science ®Google Scholar
• Brutsche MH, Downs, SH, Schindler, C et al. Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA Cohort Study. Thorax. 2006 Aug;61(8):671–677. doi: 10.1136/THX.2005.052241
   PubMed Web of Science ®Google Scholar
• Nerpin E, Ferreira DS, Weyler J, et al. Bronchodilator response and lung function decline: Associations with exhaled nitric oxide with regard to sex and smoking status. World Allergy Organ J. 2021 May;14(5):100544.
   PubMed Web of Science ®Google Scholar
• Hancox RJ, Pavord ID, Sears MR. Associations between blood eosinophils and decline in lung function among adults with and without asthma. Eur Respir J. 2018 Apr;51(4). doi: 10.1183/13993003.02536-2017
   Web of Science ®Google Scholar
• Vedel-Krogh S, Nielsen SF, Lange P, et al. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. the copenhagen general population Study. Am J Respir Crit Care Med. 2016 May;193(9):965–974. doi: 10.1164/RCCM.201509-1869OC
   PubMed Web of Science ®Google Scholar
• Yun JH, Lamb A, Chase R, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018 Jun;141(6):2037–2047.e10.
   PubMed Web of Science ®Google Scholar
• Komura M, Sato T, Suzuki Y, et al. Blood eosinophil count as a predictive biomarker of chronic obstructive pulmonary disease exacerbation in a real-world setting. Can Respir J. 2023;2023:1–8. doi: 10.1155/2023/3302405
   Web of Science ®Google Scholar
• Cui Y, Zhang W, Ma Y, et al. Stability of blood eosinophils in acute exacerbation of chronic obstructive pulmonary disease and its relationship to clinical outcomes: a prospective cohort study. Respir Res. 2021 Dec;22(1). doi: 10.1186/S12931-021-01888-5
   Web of Science ®Google Scholar
• Alcázar-Navarrete B, Díaz-Lopez JM, García-Flores P, et al. T2 Biomarkers as predictors of exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol. 2022 Aug;58(8):595–600.
   PubMed Web of Science ®Google Scholar
• Csoma B, Bikov A, Tóth F, et al. Blood eosinophils on hospital admission for COPD exacerbation do not predict the recurrence of moderate and severe relapses. ERJ Open Res. 2021;7(1):1–8. doi: 10.1183/23120541.00543-2020
   Google Scholar
• Lázár Z, Kelemen A, Gálffy G, et al. Central and peripheral airway nitric oxide in patients with stable and exacerbated chronic obstructive pulmonary disease. J Breath Res. 2018 May;12(3):036017. doi: 10.1088/1752-7163/AAC10A
   PubMed Web of Science ®Google Scholar
• Kostakou E, Kaniaris, E., Filiou, E et al. Acute severe asthma in adolescent and adult patients: current perspectives on assessment and management. J Clin Med. 2019 Sep;8(9):1283.
   PubMed Web of Science ®Google Scholar
• Busse WW, Wenzel SE, Casale TB, et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respir Med. 2021 Oct;9(10):1165–1173.
   PubMed Web of Science ®Google Scholar
• Ricciardolo FLM, Sorbello V, Ciprandi G. A pathophysiological approach for FeNO: A biomarker for asthma. Allergol Immunopathol (Madr). 2015 Nov;43(6):609–616. doi: 10.1016/J.ALLER.2014.11.004
   PubMed Web of Science ®Google Scholar
• Gulati K, Thokchom SK, Ray A, et al. Nitric oxide as a diagnostic and therapeutic tool in respiratory diseases. Adv Biochem Health Disease. 2023;22:223–248. doi: 10.1007/978-3-031-24778-1_11
   Google Scholar
• Malerba M, Radaeli A, Olivini A, et al. Exhaled nitric oxide as a biomarker in COPD and related comorbidities. Biomed Res Int. 2014;2014:1–7. doi: 10.1155/2014/271918
   Web of Science ®Google Scholar
• Ragnoli B, Radaeli A, Pochetti P, et al. Fractional nitric oxide measurement in exhaled air (FeNO): perspectives in the management of respiratory diseases. Ther Adv Chronic Dis. 2023 Jan;14. doi: 10.1177/20406223231190480
   PubMed Web of Science ®Google Scholar
• Ruzsics I, Nagy L, Keki S, et al. L-Arginine pathway in COPD patients with acute exacerbation: a new potential biomarker. COPD: J Chronic Obstructive Pulmonary Dis. 2016 Mar;13(2):139–145.
   PubMed Web of Science ®Google Scholar
• Zhou A, Zhou Z, Deng D, et al. The value of FENO measurement for predicting treatment response in patients with acute exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2020;15:2257–2266. doi: 10.2147/COPD.S263673
   PubMed Web of Science ®Google Scholar
• Río Ramírez MT, Juretschke Moragues MA, Fernández González R, et al. Value Of exhaled nitric oxide (FeNO) and eosinophilia during the exacerbations of chronic obstructive pulmonary disease requiring hospital admission. COPD: J Chronic Obstructive Pulmonary Dis. 2018 Jul;15(4):369–376.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018 Feb;6(2):117–126.
   PubMed Web of Science ®Google Scholar
• Liu Y, Ma G, Mou Y, et al. The combined value of Type2 inflammatory markers in chronic obstructive pulmonary disease. J Clin Med. 2022 May;11(10):2791.
   PubMed Web of Science ®Google Scholar
• Alcázar-Navarrete B, Rodríguez OR, Baena PC, et al. Persistently elevated exhaled nitric oxide fraction is associated with increased risk of exacerbation in COPD. Eur Respir J. 2018;51(1). doi: 10.1183/13993003.01457-2017
   PubMed Web of Science ®Google Scholar
• Schumann DM, Papakonstantinou E, Kostikas K, et al. Variability of fractional exhaled nitric oxide is associated with the risk and aetiology of COPD exacerbations. Respirology. 2023 May;28(5):445–454. doi: 10.1111/RESP.14439
   PubMed Web of Science ®Google Scholar
• Högman M, Thornadtsson A, Bröms K, et al. Different relationships between FENO and COPD characteristics in smokers and ex-smokers. COPD: J Chronic Obstructive Pulmonary Dis. 2019 Jul;16(3–4):227–233.
   PubMed Web of Science ®Google Scholar
• Gong S, Pu Y, Xie L, et al. Fraction of exhaled nitric oxide is elevated in patients with stable chronic obstructive pulmonary disease: a meta-analysis. Am J Med Sci. 2020 Aug;360(2):166–175. doi: 10.1016/J.AMJMS.2020.04.038
   PubMed Web of Science ®Google Scholar
• Chan MC, Yeung YC, Yu ELM, et al. Blood eosinophil and risk of exacerbation in chronic obstructive pulmonary disease patients: a retrospective cohort analysis. Int J Chron Obstruct Pulmon Dis. 2020;15:2869–2877. doi:10.2147/COPD.S268018
   PubMed Web of Science ®Google Scholar
• Siddiqui SH, Guasconi A, Vestbo J, et al. Blood Eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015 Aug;192(4):523–525.
   PubMed Web of Science ®Google Scholar
• Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015 Jun;3(6):435–442. doi: 10.1016/S2213-2600(15)00106-X
   PubMed Web of Science ®Google Scholar
• Chou KT, Su K-C, Huang S-F, et al. Exhaled nitric oxide predicts eosinophilic airway inflammation in COPD. Lung. 2014;192(4):499–504. doi: 10.1007/S00408-014-9591-8
   PubMed Web of Science ®Google Scholar
• Kostikas K, Papathanasiou E, Papaioannou AI, et al. Blood eosinophils as predictor of outcomes in patients hospitalized for COPD exacerbations: a prospective observational study. Biomarkers. 2021;26(4):354–362. doi: 10.1080/1354750X.2021.1903998
   PubMed Web of Science ®Google Scholar
• Soter S, Barta I, Antus B. Predicting sputum eosinophilia in exacerbations of COPD using exhaled nitric oxide. Inflammation. 2013 Oct;36(5):1178–1185. doi: 10.1007/S10753-013-9653-8
   PubMed Web of Science ®Google Scholar
• Barnes NC, Sharma R, Lettis S, et al. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J. 2016 May;47(5):1374–1382. doi: 10.1183/13993003.01370-2015
   PubMed Web of Science ®Google Scholar
• Brightling CE, McKenna, S, Hargadon, B et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax. 2005 Mar;60(3):193–198. doi: 10.1136/THX.2004.032516
   PubMed Web of Science ®Google Scholar
• Singh D, Wedzicha JA, Siddiqui S, et al. Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. Respir Res. 2020 Sep;21(1). doi: 10.1186/S12931-020-01482-1
   Web of Science ®Google Scholar
• Mathioudakis AG, Bikov A, Foden P, et al. Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD. Eur Respir J. 2020 Apr;55(5):1902119.
   PubMed Web of Science ®Google Scholar
• Vincken S, Sylvia V, Daniel S, et al. The role of FeNO in stable COPD patients with eosinophilic airway inflammation. Respir med. 2021 May;181. doi: 10.1016/J.RMED.2021.106377
   PubMed Web of Science ®Google Scholar
• Yamaji Y, Oishi K, Hamada K, et al. Detection of type2 biomarkers for response in COPD. J Breath Res. 2020;14(2):026007. doi: 10.1088/1752-7163/AB71A4
   PubMed Web of Science ®Google Scholar
• Kunisaki KM, Rice KL, Janoff EN, et al. Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study. Ther Adv Respir Dis. 2008;2(2):55–64. doi: 10.1177/1753465808088902
   PubMedGoogle Scholar
• Akamatsu K, Matsunaga K, Sugiura H, et al. Improvement of airflow limitation by fluticasone propionate/salmeterol in chronic obstructive pulmonary disease: what is the specific marker?. Front Pharmacol. 2011;2. doi: 10.3389/FPHAR.2011.00036
   PubMed Web of Science ®Google Scholar
• Pavord, ID, Chanez, P, Criner, GJ et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017 Jan;377(10):986–987.
   PubMed Web of Science ®Google Scholar
• Criner GJ, Celli BR, Brightling CE, et al. Benralizumab for the prevention of COPD exacerbations. N Engl J Med. 2019 Sep;381(11):1023–1034.
   PubMed Web of Science ®Google Scholar
• Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023 Jul;389(3):205–214. doi: 10.1056/NEJMOA2303951
   PubMed Web of Science ®Google Scholar
• Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease. [cited 2024 Jan 12]. Available from: https://www.sanofi.com/en/media-room/press-releases/2023/2023-11-27-06-30-00-2785836
   Google Scholar
• 2023 GINA Main Report - Global Initiative for Asthma - GINA. [cited 2024 Mar 3]. Available from: https://ginasthma.org/2023-gina-main-report/
   Google Scholar
• Barrecheguren M, Pinto L, Mostafavi‐Pour‐Manshadi SMY, et al. Identification and definition of asthma–COPD overlap: The CanCOLD study. Respirology. 2020 Aug;25(8):836–849.
   PubMed Web of Science ®Google Scholar
• Sin DD, Miravitlles M, Mannino DM, et al. What is asthma−COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J. 2016 Sep;48(3):664–673.
   PubMed Web of Science ®Google Scholar
• Leung C, Sin DD. Asthma-COPD overlap: what are the important questions?. Chest. 2022 Feb;161(2):330–344. doi: 10.1016/j.chest.2021.09.036
   PubMed Web of Science ®Google Scholar
• Alsayed AR, Abu-Samak MS, Alkhatib M. Asthma-COPD Overlap in clinical practice (ACO_CP 2023): toward precision medicine. J Pers Med. 2023 Apr;13(4):677. doi: 10.3390/JPM13040677
   PubMed Web of Science ®Google Scholar
• Andreeva E, Pokhaznikova M, Lebedev A, et al. Spirometry is not enough to diagnose COPD in epidemiological studies: a follow-up study. NPJ Prim Care Respir Med. 2017 Dec;27(1). doi: 10.1038/S41533-017-0062-6
   Google Scholar
• Park J, Hobbs BD, Crapo JD, et al. Subtyping COPD by using visual and quantitative CT imaging features. Chest. 2020 Jan;157(1):47–60.
   PubMed Web of Science ®Google Scholar
• Singla S, Gong M, Riley C, et al. Improving clinical disease subtyping and future events prediction through a chest CT-based deep learning approach. Med Phys. 2021 Mar;48(3):1168–1181. doi: 10.1002/MP.14673
   PubMed Web of Science ®Google Scholar
• Telenga ED, Oudkerk M, van Ooijen PMA, et al. Airway wall thickness on HRCT scans decreases with age and increases with smoking. BMC Pulm Med. 2017 Feb;17(1). doi: 10.1186/S12890-017-0363-0
   PubMedGoogle Scholar
• Grydeland TB, Dirksen A, Coxson HO, et al. Quantitative computed tomography: emphysema and airway wall thickness by sex, age and smoking. Eur Respir J. 2009 Oct;34(4):858–865.
   PubMed Web of Science ®Google Scholar
• Kahnert K, Jörres RA, Kauczor H-U, et al. Standardized airway wall thickness Pi10 from routine CT scans of COPD patients as imaging biomarker for disease severity, lung function decline, and mortality. Ther Adv Respir Dis. 2023 Jan;17:175346662211486. doi: 10.1177/17534666221148663
   Web of Science ®Google Scholar
• Charbonnier JP, Pompe E, Moore C, et al. Airway wall thickening on CT: relation to smoking status and severity of COPD. Respir med. 2019 Jan;146:36. doi: 10.1016/J.RMED.2018.11.014
   PubMed Web of Science ®Google Scholar
• Arakawa H, Fujimoto K, Fukushima Y, et al. Thin-section CT imaging that correlates with pulmonary function tests in obstructive airway disease. Eur J Radiol. 2011 Nov;80(2). doi: 10.1016/J.EJRAD.2010.06.010
   PubMed Web of Science ®Google Scholar
• Nakano Y, Muro S, Sakai H, et al. Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am J Respir Crit Care Med. 2000;162(3):1102–1108. doi: 10.1164/AJRCCM.162.3.9907120
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Nasuhara Y, Onodera Y, et al. Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006 Jun;173(12):1309–1315.
   PubMed Web of Science ®Google Scholar
• Lynch DA, Austin JHM, Hogg JC, et al. CT-Definable subtypes of chronic obstructive pulmonary disease: a statement of the fleischner society. Radiology. 2015 May;277(1):192–205.
   PubMed Web of Science ®Google Scholar
• Johannessen A, Skorge TD, Bottai M, et al. Mortality by level of emphysema and airway wall thickness. Am J Respir Crit Care Med. 2013 Mar;187(6):602–608.
   PubMed Web of Science ®Google Scholar
• Crossley D, Renton M, Khan M, et al., CT densitometry in emphysema: a systematic review of its clinical utility. Int J Chron Obstruct Pulmon Dis. 2018 Feb;13:547–563. doi: 10.2147/COPD.S143066
   PubMed Web of Science ®Google Scholar
• Schroeder JD, McKenzie AS, Zach JA, et al. Relationships between airflow obstruction and quantitative CT measurements of emphysema, air trapping, and airways in subjects with and without chronic obstructive pulmonary disease. AJR Am J Roentgenol. 2013 Sep;201(3):W460–W470.
   PubMed Web of Science ®Google Scholar
• Grydeland TB, Thorsen E, Dirksen A, et al. Quantitative CT measures of emphysema and airway wall thickness are related to D(L)CO. Respir med. 2011 Mar;105(3):343–351.
   PubMed Web of Science ®Google Scholar
• Nambu A, Zach J, Kim SS, et al. Significance of low-attenuation cluster analysis on quantitative CT in the evaluation of chronic obstructive pulmonary disease. Korean J Radiol. 2018 Jan;19(1):139–146.
   PubMed Web of Science ®Google Scholar
• Mohamed Hoesein FAA, Schmidt M, Mets OM, et al. Discriminating dominant computed tomography phenotypes in smokers without or with mild COPD. Respir med. 2014 Jan;108(1):136–143.
   PubMed Web of Science ®Google Scholar
• Galbán CJ, Han MK, Boes JL, et al. Computed tomography–based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med. 2012 Nov;18(11):1711–1715.
   PubMed Web of Science ®Google Scholar
• Bodduluri S, Reinhardt JM, Hoffman EA, et al. Signs of gas trapping in normal lung density regions in smokers. Am J Respir Crit Care Med. 2017 Dec;196(11):1404–1410.
   PubMed Web of Science ®Google Scholar
• Chung KF, Cytokines in chronic obstructive pulmonary disease - pubMed. [cited 2024 Jan 11]. Available from: https://pubmed.ncbi.nlm.nih.gov/12392035/
   Google Scholar
• Bhowmik A, Seemungal TAR, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55(2):114–120. doi:10.1136/THORAX.55.2.114
   PubMed Web of Science ®Google Scholar
• Mercer PF, Shute JK, Bhowmik A, et al. MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. Respir Res. 2005 Dec;6(1):1–9.
   PubMedGoogle Scholar
• Wells JM, Parker MM, Oster RA, et al. Elevated circulating MMP-9 is linked to increased COPD exacerbation risk in SPIROMICS and COPDGene. JCI Insight. 2018 Nov;3(22). doi: 10.1172/JCI.INSIGHT.123614
   Web of Science ®Google Scholar
• Dasgupta A, Chakraborty R, Saha B, et al. Sputum protein biomarkers in airway diseases: a pilot study. Int J Chron Obstruct Pulmon Dis. 2021 Jul;16:2203–2215. doi: 10.2147/COPD.S306035
   PubMed Web of Science ®Google Scholar
• Mallia-Milanes B, Dufour A, Philp C, et al. TAILS proteomics reveals dynamic changes in airway proteolysis controlling protease activity and innate immunity during COPD exacerbations. Am J Physiol Lung Cell Mol Physiol. 2018 Dec;315(6):L1003–L1014.
   PubMed Web of Science ®Google Scholar
• Fang H, Liu Y, Yang Q, et al. Prognostic biomarkers based on proteomic technology in COPD: a recent review. Int J COPD. 2023;18:1353–1365. doi: 10.2147/COPD.S410387
   Google Scholar
• Broeckaert F, Bernard A. Clara cell secretory protein (CC16): characteristics and perspectives as lung peripheral biomarker. Clin Exp Immunol. 2000 Apr;30(4):469–475. doi: 10.1046/J.1365-2222.2000.00760.X
   Google Scholar
• Shijubo N, Itoh Y, Yamaguchi T, et al. Serum and BAL Clara cell 10 kDa protein (CC10) levels and CC10-positive bronchiolar cells are decreased in smokers. Eur Respir J. 1997;10(5):1108–1114. doi: 10.1183/09031936.97.10051108
   PubMed Web of Science ®Google Scholar
• Ravi AK, Khurana S, Lemon J, et al. Increased levels of soluble interleukin-6 receptor and CCL3 in COPD sputum. Respir Res. 2014 Sep;15(1). doi: 10.1186/S12931-014-0103-4
   PubMedGoogle Scholar
• Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J. 2008 Jun;31(6):1334–1356. doi: 10.1183/09031936.00018908
   PubMed Web of Science ®Google Scholar
• Gernez Y, Tirouvanziam R, Chanez P. Neutrophils in chronic inflammatory airway diseases: can we target them and how? Eur Respir J. 2010;35(3):467–469. doi: 10.1183/09031936.00186109
   PubMed Web of Science ®Google Scholar
• Jacob F, Novo CP, Bachert C, et al. Purinergic signaling in inflammatory cells: P2 receptor expression, functional effects, and modulation of inflammatory responses. Purinergic Signal. 2013 Sep;9(3):285–306. doi: 10.1007/S11302-013-9357-4
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Weiss DS, Newton K, et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature. 2006 Mar;440(7081):228–232.
   PubMed Web of Science ®Google Scholar